Learn how Baysient’s T3 application customizes Vedolizumab IV dosing for smaller patients. This video demonstrates how T3 uses patient-specific data to optimize dosing intervals, ensuring therapeutic targets are achieved while minimizing risks for patients.

Key highlights include:

✔ Insights on tailoring Vedolizumab IV therapy for smaller body weights.

✔ Tools to assess how dosing adjustments affect remission potential and antibody risk.

✔ Visual simulations that show the time required to reach therapeutic trough levels.

Watch to see how T3 empowers providers to move beyond standard dosing regimens, providing personalized care that enhances patient outcomes and treatment durability.